Cargando…
Comprehensive exploratory autoantibody profiling in patients with early rheumatoid arthritis treated with methotrexate or tocilizumab
BACKGROUND: We sought to identify immunoglobin G autoantibodies predictive of early treatment response to methotrexate, the recommended first-line therapy for patients with newly diagnosed rheumatoid arthritis, and to the interleukin-6 receptor inhibitor biologic tocilizumab, initiated as the first...
Autores principales: | Teitsma, Xavier M., Devenport, Jenny, Jacobs, Johannes W. G., Pethö-Schramm, Attila, Borm, Michelle E. A., Budde, Petra, Bijlsma, Johannes W. J., Lafeber, Floris P. J. G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7728181/ https://www.ncbi.nlm.nih.gov/pubmed/33301475 http://dx.doi.org/10.1371/journal.pone.0241189 |
Ejemplares similares
-
Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy
por: Teitsma, Xavier M., et al.
Publicado: (2017) -
Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology
por: Teitsma, Xavier M, et al.
Publicado: (2018) -
Efficacy of Tocilizumab Monotherapy Versus Tocilizumab and Methotrexate Combination Therapy in the Prevention of Radiographic Progression in Rheumatoid Arthritis: An Analysis Using Individual Patient Data From Multiple Clinical Trials
por: Verhoeven, Maxime M. A., et al.
Publicado: (2022) -
Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials
por: Teitsma, Xavier M., et al.
Publicado: (2016) -
Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate
por: Verhoeven, Maxime M A, et al.
Publicado: (2020)